# The Intersection of Biotech, Patent Law, and AI with Dr. Kate Neville, IP Attorney

Page: https://stenobird.com/podcast/biotalk-unzipped-6702602/the-intersection-of-biotech-patent-law-and-ai-with-dr-kate-neville-ip-attorney
Text version: https://stenobird.com/podcast/biotalk-unzipped-6702602/the-intersection-of-biotech-patent-law-and-ai-with-dr-kate-neville-ip-attorney.md
Podcast: [BioTalk Unzipped](https://stenobird.com/podcast/biotalk-unzipped-6702602)
Published: 2026-02-16T18:35:00+00:00
Episode link: https://biotalk-unzipped.captivate.fm/episode/biotech-patent-strategy-ai-freedom-to-operate
Audio file: https://episodes.captivate.fm/episode/9a18e00c-51de-4354-9987-f02ad0d5ff9b.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/biotalk-unzipped-6702602/episodes/the-intersection-of-biotech-patent-law-and-ai-with-dr-kate-neville-ip-attorney
Duration seconds: 3165

## Resource

Recorded October 31, 2025 In this episode of BioTalk Unzipped , Gregory Austin and Dr. Chad Briscoe sit down with Dr. Kate Neville, immunologist turned seasoned biotech patent attorney at Marshall, Gerstein & Borun, to unpack one of the most misunderstood and mission-critical areas of life sciences: intellectual property. If you are a biotech founder, scientist, executive, or investor, this conversation is essential listening. We explore what patent prosecution really means, when startups should begin thinking about IP protection, how “freedom to operate” can determine commercial viability, and how emerging AI tools are reshaping the patent landscape. Dr. Neville brings 25+ years of experience guiding university spin-outs, biotech startups, and global pharmaceutical companies through complex patent strategy. She has helped secure patents for FDA-approved drugs and offers a rare dual perspective as both scientist and attorney. In This Episode We Discuss: • The difference between patent prosecution and patent litigation • Why it is never too early for biotech startups to think about IP • The U.S. one-year grace period vs. Europe’s stricter disclosure rules • What “Freedom to Operate” really means for commercialization • Antibody patents, CDR regions, and the doctrine of equivalents • How premature disclosure can impact global patent strategy • The real-world back-and-forth of patent office “office actions” • AI-assisted prior art search at the USPTO — opportunity or risk? • How funding cycles influence patent filing decisions • Women in biotech leadership and venture funding disparities • The most rewarding part of protecting life-changing therapies We also break down the USPTO’s new AI pilot programs designed to modernize patent examination and discuss how artificia…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/biotalk-unzipped-6702602/episodes/the-intersection-of-biotech-patent-law-and-ai-with-dr-kate-neville-ip-attorney/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/biotalk-unzipped-6702602/the-intersection-of-biotech-patent-law-and-ai-with-dr-kate-neville-ip-attorney.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.